Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PAG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PAG1 Recombinant Cytoplasmic Domain / Phosphomimetic Mutants High purity (>95%), Endotoxin controlled. Sequence Verified. |
View PAG1 Products |
| Gene Delivery | PAG1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling reconstitution. |
View PAG1 Products |
| Benchmark Ab | Anti-PAG1 Recombinant Antibody Recombinant positive control for flow cytometry and Western blot. |
View PAG1 Products |
| Validator | PAG1 siRNA Set For target knockdown and specificity validation. |
View PAG1 Products |
| Related Target A | CSK (C-terminal Src Kinase) Direct intracellular binding partner recruited by phosphorylated PAG1 to suppress T-cell activation. |
View CSK Products |
| Related Target B | LCK (Lymphocyte-Specific Protein Tyrosine Kinase) Key downstream effector kinase regulated by the PAG1-CSK inhibitory complex. |
View LCK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting PAG1-CSK Interaction | High-purity recombinant PAG1 cytoplasmic domain and active CSK proteins available for biochemical binding assays. |
| Intracellular Localization & Signaling | Lentiviral vectors optimized for stable expression in Jurkat or other immune cell lines to preserve lipid raft microdomain localization. |
| Lack of Controls | Sequence-verified benchmark antibodies and positive control constructs included. |
| False Positives in Screening | Validated siRNA knockdown pools included for target-specific functional validation. |
Live PAG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PAG1 therapeutics is intensifying, with major players shifting focus from traditional extracellular monoclonal antibodies to intracellular protein-protein interaction (PPI) disruptors and targeted protein degraders (PROTACs). Because PAG1 (Csk-binding protein) possesses an extremely short extracellular domain (approx. 16 amino acids) and a massive cytoplasmic signaling domain, classical therapeutic antibodies are highly restricted. The next wave of R&D is targeting the intracellular PAG1-CSK interface to release the "brakes" on Src family kinases (SFKs) in tumor-infiltrating lymphocytes.
By preventing CSK recruitment to lipid rafts, drug candidates rescue LCK/FYN activity, restoring T-cell receptor (TCR) sensitivity in immunosuppressive tumor microenvironments. Combination therapies pairing PAG1 pathway inhibitors with established anti-PD-1/PD-L1 biologics represent a major frontier in overcoming adaptive resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Biotech / Academic Consortia | Solid Tumors, Glioblastoma | TR-FRET or FP assays (Need high-purity recombinant cytoplasmic domain & CSK partner) |
| PROTACs / Degraders | Emerging Biopharma | Hematological Malignancies | Degradation kinetics assays (Need lentivirus for stable cell line construction & validated antibodies) |
| RNA Therapeutics (siRNA/ASO) | Preclinical Immuno-oncology Players | Autoimmune Diseases, Cancer | In vitro knockdown efficiency (Need validated siRNA sets and transfection-ready controls) |